Expired
Section
Original release date:
April 1, 2020
Access to this course expires on: December 6, 2022 at 11:59 PM Pacific Time
CME 12.25
Course Description
The diagnosis of soft tissue and bone tumors can be a significant challenge, even to the experienced surgical pathologist, due to the rarity of such tumors, the broad morphological spectrum of mesenchymal neoplasms, and overlap with other soft tissue and bone tumors and non-mesenchymal neoplasms. The classification of soft tissue and bone tumors continues to evolve, following the description of "new" tumor types, the discovery of novel molecular genetic alterations, and the development of increasingly specific diagnostic immunohistochemical markers; these changes are included in the new World Health Organization (WHO) Classification of Tumours of Soft Tissue and Bone. Surgical pathologists are not familiar with the current classification of soft tissue and bone tumors and recently developed diagnostic markers and struggle with accurate diagnosis. This course, presented by experts, will help to alleviate that struggle and provide pragmatic information for immediate practice improvement.
Target Audience
Practicing academic and community pathologists, and pathologists-in-training
Learning Objectives
Upon completion of this educational activity, learners will be able to:
Continuing Medical Education
The United States and Canadian Academy of Pathology is accredited by the Accreditation Council for Continuing Medical Education
(ACCME) to provide continuing medical education for physicians.
The United States and Canadian Academy of Pathology designates this enduring material for a maximum of 12.25
AMA PRA
Category 1 Credits
TM. Physicians should claim only the credit commensurate with the extent of their
participation in the activity.
Beginning in 2021, the American Board of Pathology (ABPath) will no longer require Self-Assessment Modules (SAMs) for Part II Lifelong Learning of the Continuing Certification program. For additional information, visit the
ABPath website.
Disclosures
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to
USCAP and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12
months with any commercial interest(s) whose products or services are related to the CME content. USCAP has reviewed all
disclosures and resolved or managed all identified conflicts of interest, as applicable.
The following faculty reported relevant financial relationships: Jason L. Hornick, MD, PhD,
Consultant, Eli Lilly, Epizyme; Jessica L. Davis, MD, Consultant, Bayer Pharmaceuticals
The following faculty reported no relevant financial relationships: G. Petur Nielsen, MD, Khin Thway, MD, FRCPath
The following IM Coordinator who planned and reviewed content for this activity reported no relevant financial relationships: Steven D. Billings, MD
USCAP staff associated with the development of content for this activity reported no relevant financial relationships.
To earn CME credit, all learners must complete the evaluation. Your certificate will be available to view and print by clicking here.
Buy the entire Updates from the New WHO Classification of Soft Tissue and Bone Tumors course and get a great discount!
Not A Member? Click Here